Zambon has completed the patient enrolment of patients in its two pivotal Phase III trials of Liposomal Cyclosporine A for Inhalation (L-CsA-i) to treat bronchiolitis obliterans syndrome (BOS).
Designed to assess the safety and efficacy of L-CsA-i, the trials have enrolled adults with BOS following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation.
Go deeper with GlobalData
A total of 231 patients from Europe, Israel and the US were enrolled for both the studies and 42 lung transplant centres have participated altogether.
Zambon chief medical officer and R&D head Paola Castellani said: “The completion of enrolment in our Phase III BOSTON-1 and BOSTON-2 studies represents a significant milestone for Zambon and the patient community we aim to serve.
“On behalf of the company, we would like to thank the many participants in our Phase III clinical programme, as well as our study sites and investigators for their commitment. We look forward to reporting top-line results from the programme during 2024.”
See Also:
The company also plans to initiate an extension study, BOSTON-3, and enrol eligible patients who complete both trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAn inhaled therapy, L-CsA-i is administered using the optimised investigational eFlow Technology nebuliser system, developed by PARI Pharma.
A rapidly progressive inflammatory rare disease, BOS irreversibly destroys the lungs’ airways leading to respiratory failure and death within two to four years following diagnosis.
